Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-10

AUTHORS

Gerald Chi, Megan K. Yee, Arzu Kalayci, Mathieu Kerneis, Fahad AlKhalfan, Roxana Mehran, Christoph Bode, Jonathan L. Halperin, Freek W. A. Verheugt, Peter Wildgoose, Martin van Eickels, Gregory Y. H. Lip, Marc Cohen, Eric D. Peterson, Keith A. A. Fox, C. Michael Gibson

ABSTRACT

Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the first event, would be reduced with rivaroxaban-based regimens. In the PIONEER AF-PCI trial, 2099 patients in the modified intention-to-treat population were randomized to three groups and followed for 12 months: (1) rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N = 696); (2) rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N = 706); and (3) dose-adjusted warfarin plus DAPT (N = 697). Descriptive statistics for the number of subjects who experienced one or more bleeding events were calculated. The total number of bleeding events was compared across treatment groups using the Wei, Lin, and Weissfeld method. A total of 514 and 439 events of clinically significant bleeding and bleeding requiring medical attention occurred throughout the study. Compared to triple therapy with warfarin, rivaroxaban-based regimen was associated with a reduction in total events of clinically significant bleeding (Group 1 vs. Group 3: HR 0.64 [95% CI 0.49-0.85], p < 0.001, NNT = 11; Group 2 vs. Group 3: HR 0.62 [95% CI 0.48-0.80], p < 0.001, NNT = 10). Similarly, rivaroxaban reduced the total bleeding events requiring medical attention (Group 1 vs. Group 3: HR 0.66 [95% CI 0.49-0.89], p < 0.001, NNT = 14; Group 2 vs. Group 3: HR 0.64 [95% CI 0.48-0.85], p = 0.002, NNT = 13). Rivaroxaban-based regimen reduced the total bleeding events compared with VKA-based triple therapy in stented AF patients. One clinically significant bleeding event could be prevented with rivaroxaban use for every 10-11 patients treated, and one bleeding requiring medical attention could be prevented with rivaroxaban for every 13-14 patients treated. These data provide evidence that total bleeding events, including those beyond the first event, are reduced with rivaroxaban-based antithrombotic regimens. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01830543 (PIONEER AF-PCI). More... »

PAGES

346-350

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11239-018-1703-5

DOI

http://dx.doi.org/10.1007/s11239-018-1703-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105121728

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29943350


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Gerald", 
        "id": "sg:person.0731030274.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731030274.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yee", 
        "givenName": "Megan K.", 
        "id": "sg:person.011467211171.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011467211171.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalayci", 
        "givenName": "Arzu", 
        "id": "sg:person.0601566424.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601566424.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kerneis", 
        "givenName": "Mathieu", 
        "id": "sg:person.0665324563.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665324563.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "AlKhalfan", 
        "givenName": "Fahad", 
        "id": "sg:person.010233561454.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010233561454.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehran", 
        "givenName": "Roxana", 
        "id": "sg:person.0726307411.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726307411.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Freiburg", 
          "id": "https://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Heart Center, Department for Cardiology and Angiology I, University of Freiburg, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bode", 
        "givenName": "Christoph", 
        "id": "sg:person.07672527537.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672527537.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halperin", 
        "givenName": "Jonathan L.", 
        "id": "sg:person.0647236344.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647236344.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Onze Lieve Vrouwe Gasthuis", 
          "id": "https://www.grid.ac/institutes/grid.440209.b", 
          "name": [
            "Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Verheugt", 
        "givenName": "Freek W. A.", 
        "id": "sg:person.013551676557.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013551676557.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Janssen Pharmaceuticals, Inc., Beerse, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wildgoose", 
        "givenName": "Peter", 
        "id": "sg:person.01372476124.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372476124.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Bayer Pharmaceuticals, Inc., Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Eickels", 
        "givenName": "Martin", 
        "id": "sg:person.01215161763.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215161763.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lip", 
        "givenName": "Gregory Y. H.", 
        "id": "sg:person.013125053200.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013125053200.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Newark Beth Israel Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.416154.3", 
          "name": [
            "Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Marc", 
        "id": "sg:person.012445103462.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012445103462.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University", 
          "id": "https://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Duke Clinical Research Institute, Durham, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "Eric D.", 
        "id": "sg:person.0773236713.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773236713.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Edinburgh Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418716.d", 
          "name": [
            "Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fox", 
        "givenName": "Keith A. A.", 
        "id": "sg:person.015455016152.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015455016152.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA", 
            "PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Suite OV-540, 02215, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gibson", 
        "givenName": "C. Michael", 
        "id": "sg:person.0750215673.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750215673.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1611594", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008159889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2014.12.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011893219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2015.10.077", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047658299"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1989.10478873", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058303850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.116.025783", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063344789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.116.025783", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063344789"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10", 
    "datePublishedReg": "2018-10-01", 
    "description": "Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the first event, would be reduced with rivaroxaban-based regimens. In the PIONEER AF-PCI trial, 2099 patients in the modified intention-to-treat population were randomized to three groups and followed for 12\u00a0months: (1) rivaroxaban 15\u00a0mg once daily plus a P2Y12 inhibitor (N\u2009=\u2009696); (2) rivaroxaban 2.5\u00a0mg twice daily plus dual antiplatelet therapy (DAPT) (N\u2009=\u2009706); and (3) dose-adjusted warfarin plus DAPT (N\u2009=\u2009697). Descriptive statistics for the number of subjects who experienced one or more bleeding events were calculated. The total number of bleeding events was compared across treatment groups using the Wei, Lin, and Weissfeld method. A total of 514 and 439 events of clinically significant bleeding and bleeding requiring medical attention occurred throughout the study. Compared to triple therapy with warfarin, rivaroxaban-based regimen was associated with a reduction in total events of clinically significant bleeding (Group 1 vs. Group 3: HR 0.64 [95% CI 0.49-0.85], p\u2009<\u20090.001, NNT\u2009=\u200911; Group 2 vs. Group 3: HR 0.62 [95% CI 0.48-0.80], p\u2009<\u20090.001, NNT\u2009=\u200910). Similarly, rivaroxaban reduced the total bleeding events requiring medical attention (Group 1 vs. Group 3: HR 0.66 [95% CI 0.49-0.89], p\u2009<\u20090.001, NNT\u2009=\u200914; Group 2 vs. Group 3: HR 0.64 [95% CI 0.48-0.85], p\u2009=\u20090.002, NNT\u2009=\u200913). Rivaroxaban-based regimen reduced the total bleeding events compared with VKA-based triple therapy in stented AF patients. One clinically significant bleeding event could be prevented with rivaroxaban use for every 10-11 patients treated, and one bleeding requiring medical attention could be prevented with rivaroxaban for every 13-14 patients treated. These data provide evidence that total bleeding events, including those beyond the first event, are reduced with rivaroxaban-based antithrombotic regimens.\nCLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01830543 (PIONEER AF-PCI).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11239-018-1703-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1113719", 
        "issn": [
          "0929-5305", 
          "1573-742X"
        ], 
        "name": "Journal of Thrombosis and Thrombolysis", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "46"
      }
    ], 
    "name": "Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention", 
    "pagination": "346-350", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3b36c5cdff5113b71ba8811a463d50ce3cea746e53776307a80b0afc5c092f24"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29943350"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9502018"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11239-018-1703-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105121728"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11239-018-1703-5", 
      "https://app.dimensions.ai/details/publication/pub.1105121728"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000559.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11239-018-1703-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11239-018-1703-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11239-018-1703-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11239-018-1703-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11239-018-1703-5'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      34 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11239-018-1703-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nb25abacecb834a68be96c9d89eadb1de
4 schema:citation https://doi.org/10.1016/j.ahj.2014.12.006
5 https://doi.org/10.1016/j.jacc.2015.10.077
6 https://doi.org/10.1056/nejmoa1611594
7 https://doi.org/10.1080/01621459.1989.10478873
8 https://doi.org/10.1161/circulationaha.116.025783
9 schema:datePublished 2018-10
10 schema:datePublishedReg 2018-10-01
11 schema:description Among atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), rivaroxaban with background antiplatelet therapy significantly reduced the first occurrence of bleeding compared to triple therapy with warfarin. This study hypothesized that total bleeding events, including those beyond the first event, would be reduced with rivaroxaban-based regimens. In the PIONEER AF-PCI trial, 2099 patients in the modified intention-to-treat population were randomized to three groups and followed for 12 months: (1) rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N = 696); (2) rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N = 706); and (3) dose-adjusted warfarin plus DAPT (N = 697). Descriptive statistics for the number of subjects who experienced one or more bleeding events were calculated. The total number of bleeding events was compared across treatment groups using the Wei, Lin, and Weissfeld method. A total of 514 and 439 events of clinically significant bleeding and bleeding requiring medical attention occurred throughout the study. Compared to triple therapy with warfarin, rivaroxaban-based regimen was associated with a reduction in total events of clinically significant bleeding (Group 1 vs. Group 3: HR 0.64 [95% CI 0.49-0.85], p < 0.001, NNT = 11; Group 2 vs. Group 3: HR 0.62 [95% CI 0.48-0.80], p < 0.001, NNT = 10). Similarly, rivaroxaban reduced the total bleeding events requiring medical attention (Group 1 vs. Group 3: HR 0.66 [95% CI 0.49-0.89], p < 0.001, NNT = 14; Group 2 vs. Group 3: HR 0.64 [95% CI 0.48-0.85], p = 0.002, NNT = 13). Rivaroxaban-based regimen reduced the total bleeding events compared with VKA-based triple therapy in stented AF patients. One clinically significant bleeding event could be prevented with rivaroxaban use for every 10-11 patients treated, and one bleeding requiring medical attention could be prevented with rivaroxaban for every 13-14 patients treated. These data provide evidence that total bleeding events, including those beyond the first event, are reduced with rivaroxaban-based antithrombotic regimens. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01830543 (PIONEER AF-PCI).
12 schema:genre research_article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N43f4da630f7243dd80532ef6f22e9c47
16 Nd2f0b81925c14636ad64880624eddac4
17 sg:journal.1113719
18 schema:name Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention
19 schema:pagination 346-350
20 schema:productId N07d59df1263443759a10afff73ee001c
21 N39cbcf24fee54c99a64f96f19af91cf7
22 N469f608997274efa95e8b4041c916598
23 N7e2dc9a0fb9f4de58877a21e36e5b43d
24 Nc267d3159594443eadf78e7317a3e751
25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105121728
26 https://doi.org/10.1007/s11239-018-1703-5
27 schema:sdDatePublished 2019-04-10T21:45
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher N25519fca373d4553bc38f4e70240e9b4
30 schema:url https://link.springer.com/10.1007%2Fs11239-018-1703-5
31 sgo:license sg:explorer/license/
32 sgo:sdDataset articles
33 rdf:type schema:ScholarlyArticle
34 N07d59df1263443759a10afff73ee001c schema:name doi
35 schema:value 10.1007/s11239-018-1703-5
36 rdf:type schema:PropertyValue
37 N13ba1a3c6b8a4f5792908cf835bb30f2 schema:name Bayer Pharmaceuticals, Inc., Berlin, Germany
38 rdf:type schema:Organization
39 N25519fca373d4553bc38f4e70240e9b4 schema:name Springer Nature - SN SciGraph project
40 rdf:type schema:Organization
41 N39cbcf24fee54c99a64f96f19af91cf7 schema:name nlm_unique_id
42 schema:value 9502018
43 rdf:type schema:PropertyValue
44 N3c746be498d24631818c9e9188db93a9 rdf:first sg:person.0647236344.32
45 rdf:rest Naff205c118034c0598a86ef494198f6c
46 N3ea540b829d14594a0438f0cd3b5a046 rdf:first sg:person.0601566424.63
47 rdf:rest Nafdb62b273534e6e8765a95578dbf138
48 N43f4da630f7243dd80532ef6f22e9c47 schema:volumeNumber 46
49 rdf:type schema:PublicationVolume
50 N469f608997274efa95e8b4041c916598 schema:name pubmed_id
51 schema:value 29943350
52 rdf:type schema:PropertyValue
53 N496cb185ede44dbda6a248d70af835d0 schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
54 rdf:type schema:Organization
55 N4c3b851f9ef342a1937a5a354f72103d rdf:first sg:person.07672527537.39
56 rdf:rest N3c746be498d24631818c9e9188db93a9
57 N50ba9ab9695b4cf3af39d7c2ca9b9421 rdf:first sg:person.011467211171.43
58 rdf:rest N3ea540b829d14594a0438f0cd3b5a046
59 N562c02a90d364df2921917fe717f0f96 rdf:first sg:person.0773236713.31
60 rdf:rest Nd3c063651f694279934cd6b0dd96e16f
61 N6a17aacf42cd45c7ba83e0df70f20d19 schema:name Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
62 rdf:type schema:Organization
63 N6f87a7be3ef24895ac7138b8ffb24480 schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
64 rdf:type schema:Organization
65 N7e2dc9a0fb9f4de58877a21e36e5b43d schema:name dimensions_id
66 schema:value pub.1105121728
67 rdf:type schema:PropertyValue
68 N972f90cb84954b45b683111c3f2a0372 rdf:first sg:person.013125053200.65
69 rdf:rest Na0074912f3b743a6a8cbcd7b3968bd81
70 N9e49fafea28345a9950c4aa68bce6f97 schema:name Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
71 rdf:type schema:Organization
72 N9e554e8eba3444019f2c682d729ec786 schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
73 rdf:type schema:Organization
74 Na0074912f3b743a6a8cbcd7b3968bd81 rdf:first sg:person.012445103462.20
75 rdf:rest N562c02a90d364df2921917fe717f0f96
76 Nafdb62b273534e6e8765a95578dbf138 rdf:first sg:person.0665324563.82
77 rdf:rest Nd98f09cac0b745d691c2977453d99897
78 Naff205c118034c0598a86ef494198f6c rdf:first sg:person.013551676557.70
79 rdf:rest Ndaa90b5b49324cce8c1e5a8ec54a9429
80 Nb25abacecb834a68be96c9d89eadb1de rdf:first sg:person.0731030274.14
81 rdf:rest N50ba9ab9695b4cf3af39d7c2ca9b9421
82 Nbcb0714569334a5a943bce345c0aecb6 rdf:first sg:person.0726307411.54
83 rdf:rest N4c3b851f9ef342a1937a5a354f72103d
84 Nc267d3159594443eadf78e7317a3e751 schema:name readcube_id
85 schema:value 3b36c5cdff5113b71ba8811a463d50ce3cea746e53776307a80b0afc5c092f24
86 rdf:type schema:PropertyValue
87 Ncb6fb16066ac4426ac6cabdc9ec2e7ab schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
88 rdf:type schema:Organization
89 Nd178985d9c41461d96a4b8ff1c54a18f schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
90 rdf:type schema:Organization
91 Nd2f0b81925c14636ad64880624eddac4 schema:issueNumber 3
92 rdf:type schema:PublicationIssue
93 Nd3c063651f694279934cd6b0dd96e16f rdf:first sg:person.015455016152.15
94 rdf:rest Nf0ed4d94f6664572bc0d31ab5db1dc9e
95 Nd98f09cac0b745d691c2977453d99897 rdf:first sg:person.010233561454.36
96 rdf:rest Nbcb0714569334a5a943bce345c0aecb6
97 Ndaa90b5b49324cce8c1e5a8ec54a9429 rdf:first sg:person.01372476124.58
98 rdf:rest Nf5d67e55371649fd8abd1f9cc98b7cf5
99 Ndb549b115b1d43099295e05af34a5f74 schema:name Janssen Pharmaceuticals, Inc., Beerse, Belgium
100 rdf:type schema:Organization
101 Nf0ed4d94f6664572bc0d31ab5db1dc9e rdf:first sg:person.0750215673.07
102 rdf:rest rdf:nil
103 Nf5d67e55371649fd8abd1f9cc98b7cf5 rdf:first sg:person.01215161763.45
104 rdf:rest N972f90cb84954b45b683111c3f2a0372
105 Nf82389eab77e4e89ab131ce76862ef10 schema:name Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
106 PERFUSE Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Suite OV-540, 02215, Boston, MA, USA
107 rdf:type schema:Organization
108 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
109 schema:name Medical and Health Sciences
110 rdf:type schema:DefinedTerm
111 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
112 schema:name Clinical Sciences
113 rdf:type schema:DefinedTerm
114 sg:journal.1113719 schema:issn 0929-5305
115 1573-742X
116 schema:name Journal of Thrombosis and Thrombolysis
117 rdf:type schema:Periodical
118 sg:person.010233561454.36 schema:affiliation N9e554e8eba3444019f2c682d729ec786
119 schema:familyName AlKhalfan
120 schema:givenName Fahad
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010233561454.36
122 rdf:type schema:Person
123 sg:person.011467211171.43 schema:affiliation N6f87a7be3ef24895ac7138b8ffb24480
124 schema:familyName Yee
125 schema:givenName Megan K.
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011467211171.43
127 rdf:type schema:Person
128 sg:person.01215161763.45 schema:affiliation N13ba1a3c6b8a4f5792908cf835bb30f2
129 schema:familyName van Eickels
130 schema:givenName Martin
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215161763.45
132 rdf:type schema:Person
133 sg:person.012445103462.20 schema:affiliation https://www.grid.ac/institutes/grid.416154.3
134 schema:familyName Cohen
135 schema:givenName Marc
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012445103462.20
137 rdf:type schema:Person
138 sg:person.013125053200.65 schema:affiliation https://www.grid.ac/institutes/grid.6572.6
139 schema:familyName Lip
140 schema:givenName Gregory Y. H.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013125053200.65
142 rdf:type schema:Person
143 sg:person.013551676557.70 schema:affiliation https://www.grid.ac/institutes/grid.440209.b
144 schema:familyName Verheugt
145 schema:givenName Freek W. A.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013551676557.70
147 rdf:type schema:Person
148 sg:person.01372476124.58 schema:affiliation Ndb549b115b1d43099295e05af34a5f74
149 schema:familyName Wildgoose
150 schema:givenName Peter
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372476124.58
152 rdf:type schema:Person
153 sg:person.015455016152.15 schema:affiliation https://www.grid.ac/institutes/grid.418716.d
154 schema:familyName Fox
155 schema:givenName Keith A. A.
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015455016152.15
157 rdf:type schema:Person
158 sg:person.0601566424.63 schema:affiliation Nd178985d9c41461d96a4b8ff1c54a18f
159 schema:familyName Kalayci
160 schema:givenName Arzu
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601566424.63
162 rdf:type schema:Person
163 sg:person.0647236344.32 schema:affiliation N9e49fafea28345a9950c4aa68bce6f97
164 schema:familyName Halperin
165 schema:givenName Jonathan L.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647236344.32
167 rdf:type schema:Person
168 sg:person.0665324563.82 schema:affiliation Ncb6fb16066ac4426ac6cabdc9ec2e7ab
169 schema:familyName Kerneis
170 schema:givenName Mathieu
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665324563.82
172 rdf:type schema:Person
173 sg:person.0726307411.54 schema:affiliation N6a17aacf42cd45c7ba83e0df70f20d19
174 schema:familyName Mehran
175 schema:givenName Roxana
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726307411.54
177 rdf:type schema:Person
178 sg:person.0731030274.14 schema:affiliation N496cb185ede44dbda6a248d70af835d0
179 schema:familyName Chi
180 schema:givenName Gerald
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731030274.14
182 rdf:type schema:Person
183 sg:person.0750215673.07 schema:affiliation Nf82389eab77e4e89ab131ce76862ef10
184 schema:familyName Gibson
185 schema:givenName C. Michael
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750215673.07
187 rdf:type schema:Person
188 sg:person.07672527537.39 schema:affiliation https://www.grid.ac/institutes/grid.5963.9
189 schema:familyName Bode
190 schema:givenName Christoph
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672527537.39
192 rdf:type schema:Person
193 sg:person.0773236713.31 schema:affiliation https://www.grid.ac/institutes/grid.26009.3d
194 schema:familyName Peterson
195 schema:givenName Eric D.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773236713.31
197 rdf:type schema:Person
198 https://doi.org/10.1016/j.ahj.2014.12.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011893219
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.jacc.2015.10.077 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047658299
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1056/nejmoa1611594 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008159889
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1080/01621459.1989.10478873 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058303850
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1161/circulationaha.116.025783 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063344789
207 rdf:type schema:CreativeWork
208 https://www.grid.ac/institutes/grid.26009.3d schema:alternateName Duke University
209 schema:name Duke Clinical Research Institute, Durham, NC, USA
210 rdf:type schema:Organization
211 https://www.grid.ac/institutes/grid.416154.3 schema:alternateName Newark Beth Israel Medical Center
212 schema:name Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA
213 rdf:type schema:Organization
214 https://www.grid.ac/institutes/grid.418716.d schema:alternateName Edinburgh Royal Infirmary
215 schema:name Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK
216 rdf:type schema:Organization
217 https://www.grid.ac/institutes/grid.440209.b schema:alternateName Onze Lieve Vrouwe Gasthuis
218 schema:name Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
219 rdf:type schema:Organization
220 https://www.grid.ac/institutes/grid.5963.9 schema:alternateName University of Freiburg
221 schema:name Heart Center, Department for Cardiology and Angiology I, University of Freiburg, Freiburg, Germany
222 rdf:type schema:Organization
223 https://www.grid.ac/institutes/grid.6572.6 schema:alternateName University of Birmingham
224 schema:name Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...